GPT and neutropenia: Treatment-related adverse events (Table 2) were observed in all subjects and included leukopenia (100%), neutropenia (88%), thrombocytopenia (88%), anemia (81%), lymphopenia (77%), fatigue (69%), mucositis (62%), and ALT elevation (62%).